Systemic therapy approaches include the same treatments that have a demonstrated efficacy in cutaneous melanoma, including anti-programmed cell death protein 1 (anti-PD1) and anti-cytotoxic T-lymphocyte antigen-4 (anti-CTLA4) immune checkpoint inhibitors (ICI) [10]. Here, PDCD1 is linked to cutaneous melanoma.